scholarly journals Non-Participation in Breast Cancer Screening in Spain and Potential Application in the Present and Future: A Cross Sectional Study

Cancers ◽  
2021 ◽  
Vol 13 (17) ◽  
pp. 4331
Author(s):  
Juan José Muñoz-Sanz ◽  
María Jiménez-Palomares ◽  
Elisa María Garrido-Ardila ◽  
Juan Rodríguez-Mansilla
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Older Women ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Screening Programme ◽  
Breast Cancer Mortality ◽  
Screening Methods ◽  
Cross Sectional ◽  
Screening Programs

Background: Currently, we are beginning to observe a stabilisation and even a decrease in breast cancer mortality in the world, which may be related, among other reasons, to breast cancer screening. Methods: The objective of this study was to analyse the different reasons why women do not participate in the Breast Cancer Early Detection Programme in Extremadura (Spain) and to discuss the results, offering possible tools to improve the screening programs. This is an observational, descriptive, cross-sectional and retrospective study. A questionnaire with 14 questions was carried out by telephone or mail. Results: A total of 3970 questionnaires were collected. However, only 2507 were valid. A total of 70.36% of young and educated women underwent mammographic controls. The type of women who did not attend the screening programme appointment corresponded to a woman of approximately 60 years of age, with no formal studies, married, with children, who does not work outside their home and who lived in the health area of Badajoz. Among the main reasons for not going to the appointment, 53.9% of the women surveyed indicated that they had check-ups with their gynaecologist, and this specialist referred them for a mammograph. These women were younger and have a higher level of education. Women with a lower educational level and older women did not have any mammography done and did not undergo screening. They indicated that they did not go to the appointment because they were afraid of having a mammography (44%) or because they did not receive the appointment in time (31.6%). A total of 26.9% of the women who did not attend the appointment for other reasons stated that they had problems in attending because they had a physical limitation (dependency). Conclusions: Women who did not participate in the breast cancer screening programme in Extremadura had low educational levels and were older women. Specifically, fear of having a mammogram was the main argument raised by these women. In addition, a small group stated that they did not consider mammography to be useful. At present and in the future, good quality screening programs must be carried out to contribute to the reduction in breast cancer mortality. Furthermore, enhancing the participation of women is essential to increase the attendance rate and, therefore, the success of the screening programmes.

scholarly journals Repeated mammographic screening reduces breast cancer mortality along the continuum of age

2002 ◽  
Vol 9 (4) ◽  
pp. 163-167 ◽  
Author(s):  
M.J.M. Broeders ◽  
A.L.M. Verbeek ◽  
H. Straatman ◽  
P.G.M. Peer ◽  
P.C.M. Pasker-de Jong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Screening Programme ◽  
Breast Cancer Mortality ◽  
Mammographic Screening ◽  
Protective Effects ◽  
Age Group ◽  
The Continuum

OBJECTIVE: The optimal age boundaries for breast cancer screening are still under debate. A case-referent design was used to describe the effect of mammographic screening on breast cancer mortality along the continuum of age, based on a 20 year follow up period. SETTING: The population based breast cancer screening programme in Nijmegen, The Netherlands, which has biennially invited women over 35 years since 1975. METHODS: Cases, defined as women who died from primary breast cancer between 1987 and 1997, were selected from the group of women who received at least one invitation to the screening programme. For 157 cases, 785 women from the same group were selected as referents. Information on the index screening (the screening examination preceding diagnosis of the case) was collected for both cases and referents. The risk of dying from breast cancer was calculated per 10 year moving age group for women who had attended the index screening versus those who had not. RESULTS: The youngest 10 year age group showing an effect in our study were women aged 45–54 at their index screening. Breast cancer mortality for women in this group who attended the index screening was 32% lower, although not significant, than for women who did not (odds ratio (OR) 0.68, 95% confidence interval (95% CI) 0.33 to 1.41). This reduction in risk was not explained solely by an effect in women over 50 because the OR in women aged 45–49 was 0.56 (95% CI 0.20 to 1.61). Reductions in mortality became smaller with increasing age. Nevertheless, for women over 60 at index screening, participation in screening over a maximum 4 year period before diagnosis of the case yielded protective effects at least up to an age around 80. CONCLUSIONS: Although our results are based on a relatively small number of cases, they suggest that even in a programme with a 2 year screening interval there may be a benefit of starting screening around age 45. Also older women who participate at least once every 4 years still have much to gain from screening.

scholarly journals Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study

BMJ ◽  
2014 ◽  
Vol 349 (sep12 1) ◽  
pp. g5410-g5410 ◽  
Author(s):  
N. A. de Glas ◽  
A. J. M. de Craen ◽  
E. Bastiaannet ◽  
E. G. Op 't Land ◽  
M. Kiderlen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
The Netherlands ◽  
Older Women ◽  
Breast Cancer Screening ◽  
Screening Programme ◽  
Population Based ◽  
Population Based Study ◽  
Breast Cancer Screening Programme ◽  
Cancer Screening Programme

scholarly journals Worldwide Review and Meta-Analysis of Cohort Studies Measuring the Effect of Mammography Screening Programmes on Incidence-Based Breast Cancer Mortality

Cancers ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 976
Author(s):  
Amanda Dibden ◽  
Judith Offman ◽  
Stephen W. Duffy ◽  
Rhian Gabe
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Mammography Screening ◽  
Meta Analysis ◽  
Breast Cancer Mortality ◽  
Substantial Reduction ◽  
Healthcare Setting ◽  
Actual Attendance

In 2012, the Euroscreen project published a review of incidence-based mortality evaluations of breast cancer screening programmes. In this paper, we update this review to October 2019 and expand its scope from Europe to worldwide. We carried out a systematic review of incidence-based mortality studies of breast cancer screening programmes, and a meta-analysis of the estimated effects of both invitation to screening and attendance at screening, with adjustment for self-selection bias, on incidence-based mortality from breast cancer. We found 27 valid studies. The results of the meta-analysis showed a significant 22% reduction in breast cancer mortality with invitation to screening, with a relative risk of 0.78 (95% CI 0.75–0.82), and a significant 33% reduction with actual attendance at screening (RR 0.67, 95% CI 0.61–0.75). Breast cancer screening in the routine healthcare setting continues to confer a substantial reduction in mortality from breast cancer.

Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening

2009 ◽  
Vol 27 (35) ◽  
pp. 5919-5923 ◽  
Author(s):  
Philippe Autier ◽  
Clarisse Héry ◽  
Jari Haukka ◽  
Mathieu Boniol ◽  
Graham Byrnes
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Advanced Breast Cancer ◽  
Breast Cancer Screening ◽  
Advanced Cancer ◽  
Cancer Mortality ◽  
Breast Cancer Mortality ◽  
Advanced Breast ◽  
Published Data ◽  
National Breast

Purpose We assessed changes in advanced cancer incidence and cancer mortality in eight randomized trials of breast cancer screening. Patients and Methods Depending on published data, advanced cancer was defined as cancer ≥ 20 mm in size (four trials), stage II+ (four trials), and ≥ one positive lymph node (one trial). For each trial, we obtained the estimated relative risk (RR) and 95% CI between the intervention and control groups, for both breast cancer mortality and diagnosis of advanced breast cancer. Using a meta-regression approach, log(RR-mortality) was regressed on log(RR-advanced cancer), weighting each trial by the reciprocal of the square of the standard error of log(RR) for mortality. Results RR for advanced breast cancer ranged from 0.69 (95% CI, 0.61 to 0.78) in the Swedish Two-County Trial to 0.97 (95% CI, 0.97 to 1.25) in the Canadian National Breast Screening Study-1 (NBSS-1) trial. Log(RR)s for advanced cancer were highly predictive of log(RR)s for mortality (R2 = 0.95; P < .0001), and the linear regression curve had a slope of 1.00 (95% CI, 0.76 to 1.25) after fixing the intercept to zero. The slope changed only slightly after excluding the Two-County Trial and the Canadian NBSS-1 and NBSS-2 trials. Conclusion In trials on breast cancer screening, for each unit decrease in incidence of advanced breast cancer, there was an equal decrease in breast cancer mortality. Monitoring of incidence of advanced breast cancer may provide information on the current impact of screening on breast cancer mortality in the general population.

scholarly journals Breast cancer screening programmes in selected European countries and Poland

2021 ◽  
Vol 11 (7) ◽  
pp. 11-21
Author(s):  
Adam Jasiura ◽  
Izabela Dera ◽  
Karolina Szlachcic ◽  
Mateusz Gorzel ◽  
Joanna Zmonarska
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Mortality Rate ◽  
Breast Cancer Screening ◽  
Malignant Tumors ◽  
Breast Cancer Mortality ◽  
Breast Cancer Incidence ◽  
Screening Tests ◽  
The European Union ◽  
Screening Programs

Breast neoplasms are the most common malignant tumors among women. In recent years breast cancer incidence rate has increased. Due to this fact the European Union presents evidence-based guidelines on breast cancer screening and diagnosis. Recommended and commonly used screening test is mammography. The effectiveness of prophylaxis is measured by a decrease in breast cancer mortality rate. Detailed recommendations in EU member countries differ from those presented by the EU institutions. This paper compares the screening programme in Poland to screening programmes in other EU members. The evaluation considers compliance with European screening guidelines and changes in mortality rates since the introduction of the screening programs. General guidelines in Poland are close to European ones. However, some Polish health centers still use analog mammography instead of recommended digital mammography. Furthermore, mortality rate changes in Poland maintain on a constant level due to women’s reluctant participation in screening tests.

Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 10500-10500
Author(s):  
Kathryn P. Lowry ◽  
H. Amarens Geuzinge ◽  
Natasha K. Stout ◽  
Oguzhan Alagoz ◽  
John M. Hampton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Mortality ◽  
Breast Cancer Mortality ◽  
Breast Cancer Incidence ◽  
Simulation Models ◽  
Pathogenic Variants ◽  
Life Years ◽  
Incidence And Mortality

10500 Background: Inherited pathogenic variants in ATM, CHEK2, and PALB2 confer moderate to high risks of breast cancer. The optimal approach to screening in these women has not been established. Methods: We used two simulation models from the Cancer Intervention and Surveillance Modeling Network (CISNET) and data from the Cancer Risk Estimates Related to Susceptibility consortium (CARRIERS) to project lifetime breast cancer incidence and mortality in ATM, CHEK2, and PALB2 carriers. We simulated screening with annual mammography from ages 40-74 alone and with annual magnetic resonance imaging (MRI) starting at ages 40, 35, 30, and 25. Joint and separate mammography and MRI screening performance was based on published literature. Lifetime outcomes per 1,000 women were reported as means and ranges across both models. Results: Estimated risk of breast cancer by age 80 was 22% (21-23%) for ATM, 28% (26-30%) for CHEK2, and 40% (38-42%) for PALB2. Screening with MRI and mammography reduced breast cancer mortality by 52-60% across variants (Table). Compared to no screening, starting MRI at age 30 increased life years (LY)/1000 women by 501 (478-523) in ATM, 620 (587-652) in CHEK2, and 1,025 (998-1,051) in PALB2. Starting MRI at age 25 versus 30 gained 9-12 LY/1000 women with 517-518 additional false positive screens and 197-198 benign biopsies. Conclusions: For women with ATM, CHEK2, and PALB2 pathogenic variants, breast cancer screening with MRI and mammography halves breast cancer mortality. These mortality benefits are similar to those for MRI screening for BRCA1/2 mutation carriers and should inform practice guidelines.[Table: see text]

Breast cancer screening literacy information on online platforms: A content analysis of YouTube videos

2021 ◽  
pp. 1-7
Author(s):  
Jasleen Brar ◽  
Ayisha Khalid ◽  
Mahzabin Ferdous ◽  
Tasnima Abedin ◽  
Tanvir C. Turin
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Breast Cancer Mortality ◽  
Final Analysis ◽  
Screening Methods ◽  
Wide Audience ◽  
Healthcare Resources ◽  
Screening Guidelines ◽  
Preventative Measures

BACKGROUND: The YouTube platform has great potential of serving as a healthcare resource due to its easy accessibility, navigability and wide audience reach. Breast cancer screening is an important preventative measure that can reduce breast cancer mortality by 40%. Therefore, platforms being used as a healthcare resources, such as YouTube, can and should be used to advocate for essential preventative measures such as breast cancer screening. METHODS: In this study, the usefulness of videos related to breast cancer and breast cancer screening were analyzed. Videos were first screened for inclusion and then were categorized into very useful, moderately useful, somewhat useful, and not useful categories according to a 10-point criteria scale developed by medical professionals based on existing breast cancer screening guidelines. Two reviewers independently assessed each video using the scale. RESULTS: 200 videos were identified in the preliminary analysis (100 for the search phrase ‘breast cancer’ and 100 for the search phrase ‘breast cancer screening’). After exclusion of duplicates and non-relevant videos, 162 videos were included in the final analysis. We found the following distribution of videos: 4.3% very useful, 17.9% moderately useful, 39.5% somewhat useful, and 38.3% not useful videos. There was a significant association between each of the following and the video’s level of usefulness: video length, the number of likes, and the uploading source. Longer videos were very useful, somewhat useful videos were the most liked, personally produced videos were the most not useful, and advertisements produced the highest ratio of very useful to not useful videos. CONCLUSION: It is necessary to create more reliable and useful healthcare resources for the general population as well as to monitor health information on easily accessible social platforms such as YouTube.

scholarly journals Breast cancer screening case–control study design: impact on breast cancer mortality

2011 ◽  
Vol 22 (4) ◽  
pp. 863-869 ◽  
Author(s):  
E. Paap ◽  
A.L.M. Verbeek ◽  
D. Puliti ◽  
E. Paci ◽  
M.J.M. Broeders
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Study Design ◽  
Cancer Mortality ◽  
Case Control Study ◽  
Breast Cancer Mortality ◽  
Case Control ◽  
Control Study

scholarly journals Knowledge and Practice of Breast Cancer Screening Methods among Female Community Pharmacists in Jordan: A Cross-Sectional Study

2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Nehad M. Ayoub ◽  
Ghaith M. Al-Taani ◽  
Basima A. Almomani ◽  
Linda Tahaineh ◽  
Khawla Nuseir ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Community Pharmacists ◽  
Common Reason ◽  
Screening Methods ◽  
Cross Sectional ◽  
Female Community ◽  
The Mean ◽  
Knowledge And Practice

Objectives. Our study is aimed at exploring the knowledge and personal practice of breast cancer screening among female community pharmacists in Jordan. Methods. A cross-sectional survey was carried out using a nonrandom sample selection method for pharmacists in community pharmacies. Results. A total of 551 female pharmacists completed the questionnaire. The mean age of pharmacists was 29.1 ± 7.3 years (range 21–67), and most have bachelor degrees in pharmacy (89.1%). The mean score of knowledge of breast cancer signs and symptoms was 4.2 ± 1.5 out of 6 points (range 0–6). The mean score of knowledge of risk factors was 7.6 ± 1.9 out of 12 points (ranging from 2–12). The mean score for knowledge of screening guidelines was 2.8 ± 0.9 out of 4 points (range 0–4). Overall, 452 pharmacists (85.8%) had acceptable knowledge while 75 pharmacists (14.2%) had poor knowledge of breast cancer. Pharmacists surveyed were aware of the different screening methods of breast cancer. The percentage of pharmacists who has performed breast self-examination (BSE), clinical breast examination (CBE), and mammography was 46.6%, 16.5%, and 5.4%, respectively. The most common reason for the lack of BSE and CBE performance was the absence of breast symptoms. Not being at the age recommended for mammography was the most common reason for not undergoing this screening method. Knowledge and practice of screening methods were influenced by age, years of experience, geographic region, personal history of breast cancer, and educational level among community pharmacists. Conclusions. This study revealed some gaps in the knowledge of breast cancer among female community pharmacists. The practice of the different screening methods was suboptimal, and variable reasons were indicated for the low uptake of these screening methods. Community pharmacists need to practice preventive behaviors to a satisfactory level to encourage women in the community to adopt similar behavior.

Sign in / Sign up

Export Citation Format

Share Document